Fasudil-induced hypoxia-inducible factor-1α degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1551-1561

  Takata, Keiko ^a   Morishige, Ken Ichirou ^b   Takahashi, Toshifumi ^a   Hashimoto, Kae ^b   Tsutsumi, Seiji ^a   Yin, Limei ^a   Ohta, Tsuyoshi ^a   Kawagoe, Jun ^a   Takahashi, Kazuhiro ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; RHO FACTOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; AMIDE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; DRUG DERIVATIVE; LEUPEPTIN; MYOSIN LIGHT CHAIN; PYRIDINE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UBIQUITINATION; AUTOCRINE EFFECT; CELL MOTION; CELL NUCLEUS; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; AUTOCRINE COMMUNICATION; CELL HYPOXIA; CELL MOVEMENT; CELL NUCLEUS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUPEPTINS; MYOSIN LIGHT CHAINS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PYRIDINES; RHO-ASSOCIATED KINASES; UBIQUITINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 49849096424     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0428     Document Type: Article

References (45)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;85:1182-6.
2. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233-5.
3. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
4. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
5. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39-44.
6. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 2005;96:286-90.
9. Marx J. Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 2005;308:1248-9.
10. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-5.
11. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol1992;3:65 -71.
12. Richard DE, Berra E, Pouysségur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266:718-22.
13. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
14. 2 tension. Proc Natl Acad Sci USA 1995;92:5510-4.
15. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997;94:5667-72.
16. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-92.
17. 2 sensing. Science 2001;292:464-8.
18. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
19. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:15-26.
20. Tang N, Wang L, Esko J, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485-95.
21. Knull HR, Bose D. Reversibility of mechanical and biochemical changes in smooth muscle due to anoxia and substrate depletion. Am J Physiol 1975;229:32 9-33.
22. Wagner MC, Molitoris BA. ATP depletion alters myosin Iβ cellular location in LLC-PK1 cells. Am J Physiol 1997;272:C1680-90.
23. Loktionova SA, Kabakov AE. Protein phosphatase inhibitors and heat preconditioning prevent Hsp27 dephosphorylation, F-actin disruption and deterioration of morphology in ATP-depleted endothelial cells. FEBS Lett 1998;433:294-300.
24. Hall A. G proteins and small GTPases: distant relatives keep in touch. Science 1998;279:509-14.
25. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
26. Hirota K, Semenza GL. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 2001;276:21166-72.
27. Turcotte S, Desrosiers RR, Béliveau R. HIF-1α mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 2003;116:2247-60.
28. Hayashi M, Sakata M, Takeda T, et al. Hypoxia up-regulates hypoxia-inducible factor-1α expression through RhoA activation in trophoblast cells. J Clin Endocrinol Metab 2005;90:1712-9.
29. Mizukami Y, Fujiki K, Duerr EM, et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006;281:13957-63.
30. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
31. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol 1991;198:440-50.
32. Sawada K, Morishige K, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002;62:6015-20.
33. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
34. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
35. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001;33:409-20.
36. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996;94:1647-54.
37. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002;80:629-38.
38. Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97:1272-86.
39. Suzuki H, Seto K, Shinoda Y, et al. Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed hep G2 cells. Am J Physiol 1999;276:G92 -7.
40. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997;272:23659-67.
41. 1-S transition. J Biol Chem 2004;279:26323-30.
42. Tamura M, Nakao H, Yoshizaki H. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005;30:245-52.
43. Takanashi Y, Ishida T, Kirchmeier MJ, Shuaib A, Allen TM. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. Neurol Med Chir Tokyo 2001;41:107-13.
44. Wolfrum S, Dendorfer A, Rikitake Y. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004;24:1842-7.
45. Yin L, Morishige K, Takahashi T, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007;6:1517-25.